Clinical Studies – gabarx.com

GRX-917 is a Potent Inhibitor of the NLRP3/IL-1 Beta Inflammation Pathway
Gallery
GRX-917 is a Potent Inhibitor of the NLRP3/IL-1 Beta Inflammation Pathway

Clinical Studies

GRX-917 is a Potent Inhibitor of the NLRP3/IL-1 Beta Inflammation Pathway

Etifoxine (and therefore GRX-917) was recently shown to reduce neuroinflammation via inhibition of the NLRP3 inflammasome pathway (https://www.biorxiv.org/content/10.1101/2023.09.19.558428v1). Etifoxine inhibits the NLRP3 inflammasome pathway broadly, as shown by marked reductions of NLRP3, IL-1beta, and TNF. In addition, significant improvement in clinical scores were observed in the mouse EAE model of [...]

Richard Farrell2024-07-31T21:40:11+00:00Clinical Studies|

Precision qEEG Biomarker Demonstrates Anxiolytic Efficacy in Phase 1 GRX-917 and Phase 1 Etifoxine
Gallery
Precision qEEG Biomarker Demonstrates Anxiolytic Efficacy in Phase 1 GRX-917 and Phase 1 Etifoxine

Clinical Studies, Press Coverage, Uncategorized

Precision qEEG Biomarker Demonstrates Anxiolytic Efficacy in Phase 1 GRX-917 and Phase 1 Etifoxine

qEEG biomarkers demonstrated anxiolytic efficacy in both Phase 1 of GRX-917 and Phase 1 of etifoxine. qEEG Beta power increase Rapid-onset, sustained activity Time-dependent Exposure-dependent Increased qEEG Beta Power PD marker confirms GABAA receptor target engagement Anxiolytic efficacy biomarker For questions contact: Richard G. Farrell Chief Financial Officer Follow [...]

Richard Farrell2024-07-29T23:11:49+00:00Clinical Studies, Press Coverage, Uncategorized|